Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report
"POC testing is no longer a fringe segment—it is a central pillar of modern diagnostics," said Melissa Elder, Senior Analyst at Kalorama Information. "We see industry leaders like Abbott, Dexcom, Roche, Danaher, and Exact Sciences innovating aggressively, with POC solutions spanning blood gases, infectious disease, colon cancer, glucose monitoring, and more."
The report identifies major growth opportunities in oncology, stroke, dementia, cardiac markers, and glucose management. With transportable and handheld devices becoming more widely available, the reach of point-of-care testing is extending to urgent care centers, disaster relief zones, and at-home monitoring.
While the market is recovering from the COVID-19 testing surge of 2020–2022, momentum continues thanks to emerging technologies and the expanding need for fast, accurate, and accessible diagnostics.
Trends Shaping the Future of POC Diagnostics:
Wearables and mobile health tools
Telehealth integration
CRISPR and microfluidics innovation
Multiplexed and AI-enabled testing
Regulatory challenges and LDT policy changes
The rise of non-invasive and consumer-friendly testing
China's expanding role in the global POC landscape
Key Takeaways from the Report:
$36 Billion in Global Revenues (2024): Driven by demand in physician offices, clinics, and mobile care, with steady mid-single-digit CAGR expected through 2029.
Top Growth Areas: Oncology, stroke, dementia, cardiac, and continuous glucose monitoring (CGM).
Next-Gen Tech Impact: Innovations in CRISPR diagnostics, biosensors, and AI are transforming point-of-care capabilities.
POC Molecular Diagnostics Rise: Originally accelerated by COVID-19, molecular POC testing is gaining relevance in emergency care and field screening worldwide.
Consumer-Led Prevention: Wearables and Bluetooth-enabled tools support proactive health monitoring.
Market Leaders and Competitive Landscape
"Abbott leads the global market with over 25% share due to its expansive POC portfolio," said Elder. "Dexcom and Roche are advancing CGM and coagulation testing, while Exact Sciences is driving growth in colon cancer diagnostics. Danaher's Beckman Coulter continues to deliver in blood, cancer, and infectious disease testing."
An Essential Industry Resource
The report is a vital tool for product developers, investors, and healthcare strategists navigating market trends and emerging opportunities. It answers critical questions such as:
Where is POC testing growing fastest?
What technologies are reshaping diagnostic accessibility?
How are regulations and reimbursement shaping adoption?
What are the most promising new test types and applications?
What's Inside:
Global market forecasts through 2029
In-depth segmentation across 10+ test categories
Venue analysis (hospital, clinic, retail, home)
Competitive landscape profiles and regulatory updates
Access the Report
Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition is now available:https://kaloramainformation.com/product/worldwide-point-of-care-poc-diagnostic-tests-2025
To request the report or schedule a briefing:Sheri Davie – Kalorama Information Sales Teamsheri.davie@scienceandmedicinegroup.com
For media inquiries:Richa Singh – VP, Strategic & Insights Salesricha.singh@scienceandmedicinegroup.com
About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a leading publisher of independent market research in medical diagnostics, biotechnology, and life sciences. Our reports help global healthcare organizations, investors, and innovators make informed decisions with confidence.
View original content to download multimedia:https://www.prnewswire.com/news-releases/rapid-expansion-and-innovation-drive-36-billion-global-point-of-care-diagnostics-market-says-new-kalorama-report-302516378.html
SOURCE Kalorama Information
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Veolia Heads a Groundbreaking Wastewater Epidemiological Surveillance Across Europe
PARIS--(BUSINESS WIRE)--Regulatory News: Veolia (PARIS:VIE), the world leader in water technologies, is at the helm of a groundbreaking European epidemiological surveillance program that leverages wastewater as a real-time health indicator. The goal: detect emerging threats early and protect urban populations across the continent. Veolia will oversee the monitoring aspect of this three-year program and will analyze up to 500 wastewater samples collected from European cities in its laboratories in Spain. Each sample will undergo more than 500 in-depth analyses, targeting a wide range of pollutants, viruses, bacteria, and drug residues. This initiative is aligned with the revised European directive on wastewater treatment, which formally embeds epidemiological surveillance as a pillar of public health. It is also part of the European 'One Health' strategy, which will enable the analysis of collective behavior, the assessment of the impact of public policies, and the identification of new threats, while strengthening Europe's health sovereignty. This principle was recently reiterated in the European Strategy for Water Resilience. Estelle Brachlianoff, CEO of Veolia said: 'Being a pioneer means anticipating tomorrow's challenges, and that's exactly what we're doing here, by transforming wastewater into an early warning tool on a European scale. This project is a concrete embodiment of our GreenUp strategic plan: our environmental solutions are also solutions for the health of citizens and the resilience of European territories. We are delighted to be able to bring the Group's expertise in water treatment and environmental health to the European Union, and to pave the way for a more connected, intelligent, and preventive public health system.' The project is led by Veolia, in partnership with the CSIC (Spanish National Research Council), Cetaqua (Veolia Water Technology Center), and the University of Santiago de Compostela. It is based on more than ten years of field experience in wastewater monitoring in Madrid, Barcelona, and Seville, covering nearly a third of the Spanish population. Daniel Tugues, CEO of Veolia Spain, said: 'The Covid-19 pandemic has revealed the untapped potential of wastewater for public health monitoring. This project puts that learning into practice on a large scale. We are very proud that the expertise of our teams is recognized at the European level. Thanks to this project, Spain is at the forefront of a new approach to environmental health, combining scientific rigor, technological innovation, and a commitment to the common good.' ABOUT VEOLIA Veolia group aims to become the benchmark company for ecological transformation. Present on five continents with 215,000 employees, the Group designs and deploys useful, practical solutions for the management of water, waste and energy that are contributing to a radical turnaround of the current situation. Through its three complementary activities, Veolia helps to develop access to resources, to preserve available resources and to renew them. In 2024, the Veolia group provided 111 million inhabitants with drinking water and 98 million with sanitation, produced 42 million megawatt hours of energy and treated 65 million tonnes of waste. Veolia Environnement (Paris Euronext: VIE) achieved consolidated revenue of 44.7 billion euros in 2024.
Medscape
2 hours ago
- Medscape
Pemphigoid or Psoriasis? 65-Year-Old's Remote Diagnosis Race
Patients with cancer often require specialised care at centres located far from their residence. During the COVID-19 pandemic, telemedicine has rapidly gained ground as a way to ease system pressures and maintain continuity of care. A 65-year-old man developed severe cutaneous toxicity, presenting as a rare bullous pemphigoid (BP) rash after 2 years on nivolumab. Notably, the reaction occurred in an outpatient setting during the COVID-19 pandemic. With coordinated support from rural providers and the use of telemedicine, his corticosteroid-refractory immune checkpoint inhibitor (ICI) toxicity was successfully managed. The case reported by Tom Marco, DO, and colleagues from the Department of Internal Medicine, University of Arizona College of Medicine, Tucson, Arizona, highlighted how remote monitoring helped diagnose and manage a rare but serious complication of cancer therapy. The Patient and His History The patient with no prior medical history presented to the emergency department with gross haematuria. A CT scan of the abdomen and pelvis revealed a large right renal mass, embracing the inferior margin of the liver without renal vein involvement or capsular extension. A CT of the chest corroborated no definite metastasis to other organs or lymph nodes. Because there was no evidence of distant metastatic disease on imaging, a right radical nephrectomy with adrenalectomy was performed by urology, without complications. The pathology report was notable for clear cell renal carcinoma. Because the patient came from a rural area, the examinations took place at a centre 3 hours away from his place of residence. The patient was subsequently examined by medical oncology, which calculated the probability of early disease progression to be low, with a recurrence rate of 8.4%. Given the low risk for recurrence, no adjuvant systemic therapy was recommended. The patient continued follow-up with medical oncology and remained under surveillance with CT scans every few months. Findings and Diagnosis At 24 months, a new right upper lobe (RUL) pulmonary nodule measuring 6 mm was found on chest CT. The nodule size was considered nonpathologic. Furthermore, the lesion was not feasible for biopsy, and the patient continued to be under close surveillance. By month 36, the RUL pulmonary nodule measured 10 mm. A new left upper lobe nodule measuring 6 mm and a new right lower lobe lesion measuring 2 mm were discovered. A follow-up PET scan showed nonavid nodules, and biopsy was not feasible. At 48 months, lesion progression prompted biopsy, which confirmed metastatic recurrence of renal cell carcinoma (RCC). The cancer was staged as IV (pT2cN0cM1). First-line treatment with nivolumab and cabozantinib was initiated. Cycles 2-5: The patient experienced mild fatigue, a grade 1 skin rash, gastrointestinal symptoms, and a 4 kg weight loss. Cycle 9: Weight loss exceeding 10% of body weight prompted cabozantinib dose reduction. Cycle 13: The patient developed diffuse skin changes, including blisters and open lesions, which led to cabozantinib discontinuation. Cycle 14: Despite stopping the TKI, he developed severe blistering skin reactions involving more than 30% of the body surface area. ICI therapy was paused, and high-dose corticosteroids were initiated. Skin biopsy confirmed BP, a rare autoimmune blistering disorder. The patient was treated with systemic corticosteroids, high-potency topical steroids, and doxycycline. Due to the limited response, rituximab was introduced for corticosteroid-refractory disease. After four doses, marked clinical improvement was observed: The skin lesions regressed, and no new blisters developed. By day 172, the patient was free of skin symptoms. Given the absence of active disease and the severity of prior toxicity, a surveillance protocol was adopted. Discussion BP is a rare but potentially life-threatening immune-related adverse event (irAE) associated with ICI therapy. Early recognition and prompt, aggressive management, including biologic agents such as rituximab, are essential to ensure optimal outcomes. The combination of ICI with TKI has become the standard therapeutic approach for the initial management of advanced RCC due to decreased mortality and increased long-term survival rates. Although this combination of medications has positively affected RCC treatment, the side effects can be severe. In this case report, it was initially suspected that cabozantinib caused cutaneous manifestations and gastrointestinal adverse effects. In numerous studies, more than 70% of patients taking cabozantinib developed one or more cutaneous toxicities, including erythema, hand-foot skin reactions with or without blisters, pruritus, seborrheic dermatitis, stomatitis, and xerosis. Alternatively, cutaneous manifestations with nivolumab have been reported in approximately 34% of patients or fewer and include maculopapular rash, eczema, lichenoid rashes, vitiligo, pruritus, and rarely, bullous eruptions. Although the dose of cabozantinib was initially reduced and eventually stopped due to multiple suspected toxicities, the patient developed a new, rapidly progressing corticosteroid-refractory rash that continued to worsen to grade 4 toxicities. The pathology was characteristic of extremely rare BP ICI toxicity. Consequently, the decision to discontinue nivolumab therapy was made. Despite discontinuation of the offending agent, his BP began to improve only after the initiation of rituximab in combination with corticosteroids. This suggests that the cutaneous toxicity was attributable to nivolumab, indicating that it was an ICI-related adverse effect. The mechanisms underlying irAEs are not fully understood. Multiple theories have been proposed, including a pro-inflammatory state, uncontrolled activity of T cells, enhanced immune activation and response, and cytokine release. Skin irAEs are the most common, encompassing 17%-40% of toxicities. This case highlights the complex care challenges faced by rural patients with cancer. The patient resided more than 3 hours from the nearest specialised oncology centre, an access barrier further compounded by the COVID-19 pandemic. With less than 7% of oncologists available in rural areas, there is a significant gap in care. The patient was able to receive cancer treatment, undergo detailed toxicity monitoring, and benefit from multidisciplinary input without a significant travel burden. Early detection and management of high-grade toxicities through remote assessments and coordinated care enabled successful treatment outcomes. Given this, structured telehealth surveillance protocols are crucial and can effectively serve rural areas that lack specialty centres.
CNN
4 hours ago
- CNN
Controversial FDA official Dr. Vinay Prasad departs agency
Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has resigned less than three months into the job. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' a spokesperson for the US Department of Health and Human Services told CNN on Tuesday. Prasad, a hematologist oncologist, was named head of the FDA's Center for Biologics Evaluation and Research in early May, giving him purview over vaccines and biologic medicines. He was subsequently also given the role of FDA chief medical and scientific officer. Like a number of Trump administration health appointees, Prasad had been a harsh critic of the government's response and vaccine policies during the Covid-19 pandemic. Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Laura Loomer, a right-wing activist with extraordinary access to President Donald Trump. Loomer had taken shots at him on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad didn't respond to requests for comment. A White House spokesperson referred a request for comment to HHS. Prasad had been defended by FDA Commissioner Dr. Marty Makary just days ago; in an interview with Politico, Makary said Prasad is an 'impeccable scientist … one of the greatest scientific minds of our generation.' 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA,' the spokesperson for HHS said. Prasad assumed his role at the FDA after years of being a vocal critic of some of the agency's drug approvals. In particular, he had railed against a decision to approve Sarepta's drug for Duchenne muscular dystrophy, Elevidys, arguing that there was little evidence it helped stall or reverse symptoms of the rare, fatal genetic disorder. This month, the FDA requested that Sarepta halt shipments of the drug after a reported death in a young patient in Brazil. Just one day before Prasad's departure, the agency made a surprising reversal and allowed Sarepta to resume shipments for certain patients. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CDER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions.
